Symbols

ARQT

Arcutis·NASDAQ

--(--)

Signals Analysis

Bullish signal 7

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Growth

High Cash/net Profit Ratio

Revenue Beats Expectation

FDA Approved

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ARQT

Arcutis Biotherapeutics, Inc.

A late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology

Industry

Biological Technology

Established Date

Listing Date

01/31/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

354

Fiscal Year Ends

12-31

Website

www.arcutis.com

Security Type

Common stock

Office address

3027 Townsgate Road Suite 300, Westlake Village, California 91361

Business

Introduction

Arcutis Biotherapeutics, Inc., formerly known as Arcutis, Inc., was established in June 2016 under the laws of the State of Delaware and later changed its name to Arcutis Biotherapeutics, Inc. The company is a late-stage biopharmaceutical company dedicated to the development and commercialization of treatments for skin diseases with unmet medical needs. The company's current product portfolio includes topical treatments with the potential to address immune-mediated skin diseases and diseases or immune skin diseases. The company's strategy is to identify and develop therapies against proven biological targets in dermatology to provide differentiated clinical features that address the major shortcomings of existing therapies in terms of target indications.

Company Financials

EPS

ARQT has released its 2025 Q4 earnings. EPS was reported at 0.13, versus the expected 0.08, beating expectations. The chart below visualizes how ARQT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ARQT has released its 2025 Q4 earnings report, with revenue of 129.50M, reflecting a YoY change of 81.48%, and net profit of 17.39M, showing a YoY change of 261.24%. The Sankey diagram below clearly presents ARQT's revenue sources and cost distribution.